Societe Generale analyst Delphine Le Louet downgrades Alcon (NYSE:ALC) from Buy to Hold.
Goldman Sachs Maintains Neutral on ACADIA Pharmaceuticals, Lowers Price Target to $15
Goldman Sachs analyst Salveen Richter maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and lowers the price target from $20 to $15.